Literature DB >> 25947193

The confusion assessment method for the intensive care unit in patients with cirrhosis.

Eric S Orman1, Anthony Perkins, Marwan Ghabril, Babar A Khan, Naga Chalasani, Malaz A Boustani.   

Abstract

In the intensive care unit (ICU), delirium is routinely measured with the widely-used, validated Confusion Assessment Method for the ICU (CAM-ICU), but CAM-ICU has not been studied in patients with cirrhosis. We studied a group of patients with cirrhosis to determine the relationship between delirium measured by CAM-ICU and clinical outcomes. Consecutive patients with cirrhosis admitted to the ICU from 2009 to 2012 were included in a retrospective cohort study. Patients were screened twice daily for coma and delirium during their ICU stay using the Richmond Agitation Sedation Scale (RASS) and CAM-ICU. The association between delirium/coma and mortality was determined using multiple logistic regression. RASS and CAM-ICU were also compared to a retrospective assessment of hepatic encephalopathy (HE). Of 91 patients with cirrhosis, 26 (28.6 %) developed delirium/coma. RASS/CAM-ICU had fair agreement with the HE assessment (κ 0.38). Patients with delirium/coma had numerically greater mortality in-hospital (23.1 vs. 7.7 %, p = 0.07) and at 90 days (30.8 vs. 18.5 %, p = 0.26), and they also had longer hospital length of stay (median 19.5 vs. 6 days, p < 0.001). Delirium/coma was associated with increased inpatient mortality, independent of disease severity (unadjusted OR 3.6; 95 % CI, 0.99-13.1; MELD-adjusted OR 5.4; 95 % CI, 1.3-23.8; acute physiology score-adjusted OR 2.2; 95 % CI, 0.53-8.9). Delirium/coma was also associated with longer length of stay after adjusting for disease severity. In critically ill patients with cirrhosis, delirium/coma as measured by the RASS and CAM-ICU is associated with increased mortality and hospital length of stay. For these patients, these measures provide valuable information and may be useful tools for clinical care. RASS and CAM-ICU need to be compared to HE-specific measures in future studies.

Entities:  

Mesh:

Year:  2015        PMID: 25947193      PMCID: PMC4492810          DOI: 10.1007/s11011-015-9679-8

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  47 in total

1.  Diagnosis, prevention, and management of delirium: summary of NICE guidance.

Authors:  John Young; Lakshmi Murthy; Maggie Westby; Anayo Akunne; Rachel O'Mahony
Journal:  BMJ       Date:  2010-07-28

2.  Large-scale implementation of sedation and delirium monitoring in the intensive care unit: a report from two medical centers.

Authors:  Brenda Truman Pun; Sharon M Gordon; Josh F Peterson; Ayumi K Shintani; James C Jackson; Julie Foss; Sharon D Harding; Gordon R Bernard; Robert S Dittus; E Wesley Ely
Journal:  Crit Care Med       Date:  2005-06       Impact factor: 7.598

3.  Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy.

Authors:  Tarek Hassanein; Andres T Blei; William Perry; Robin Hilsabeck; Jan Stange; Fin S Larsen; Robert S Brown; Stephen Caldwell; Brendan McGuire; Frederik Nevens; Robert Fontana
Journal:  Am J Gastroenterol       Date:  2009-06       Impact factor: 10.864

4.  Older adults discharged from the hospital with delirium: 1-year outcomes.

Authors:  Gail J McAvay; Peter H Van Ness; Sidney T Bogardus; Ying Zhang; Douglas L Leslie; Linda S Leo-Summers; Sharon K Inouye
Journal:  J Am Geriatr Soc       Date:  2006-08       Impact factor: 5.562

5.  Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study.

Authors:  Peter Jepsen; Peter Ott; Per Kragh Andersen; Henrik Toft Sørensen; Hendrik Vilstrup
Journal:  Hepatology       Date:  2010-05       Impact factor: 17.425

6.  Development of a clinical hepatic encephalopathy staging scale.

Authors:  M Ortiz; J Córdoba; E Doval; C Jacas; F Pujadas; R Esteban; J Guardia
Journal:  Aliment Pharmacol Ther       Date:  2007-09-15       Impact factor: 8.171

7.  Understanding international differences in terminology for delirium and other types of acute brain dysfunction in critically ill patients.

Authors:  A Morandi; P Pandharipande; M Trabucchi; R Rozzini; G Mistraletti; A C Trompeo; C Gregoretti; L Gattinoni; M V Ranieri; L Brochard; D Annane; C Putensen; U Guenther; P Fuentes; E Tobar; A R Anzueto; A Esteban; Y Skrobik; J I F Salluh; M Soares; C Granja; A Stubhaug; S E de Rooij; E Wesley Ely
Journal:  Intensive Care Med       Date:  2008-06-18       Impact factor: 17.440

Review 8.  The Confusion Assessment Method: a systematic review of current usage.

Authors:  Leslie A Wei; Michael A Fearing; Eliezer J Sternberg; Sharon K Inouye
Journal:  J Am Geriatr Soc       Date:  2008-04-01       Impact factor: 5.562

9.  Implementation, reliability testing, and compliance monitoring of the Confusion Assessment Method for the Intensive Care Unit in trauma patients.

Authors:  Stacie L Soja; Pratik P Pandharipande; Sloan B Fleming; Bryan A Cotton; Leanna R Miller; Stefanija G Weaver; Byron T Lee; E Wesley Ely
Journal:  Intensive Care Med       Date:  2008-02-23       Impact factor: 17.440

10.  The impact of organ dysfunction in cirrhosis: survival at a cost?

Authors:  Debbie L Shawcross; Mark J Austin; Robin Daniel Abeles; Mark J W McPhail; Andrew D Yeoman; Nicholas J Taylor; Andrew J Portal; Khaleel Jamil; Georg Auzinger; Elizabeth Sizer; William Bernal; Julia A Wendon
Journal:  J Hepatol       Date:  2012-01-13       Impact factor: 25.083

View more
  2 in total

1.  A modified Sequential Organ Failure Assessment score using the Richmond Agitation-Sedation Scale in critically ill patients.

Authors:  Damien Viglino; Maxime Maignan; Guillaume Debaty
Journal:  J Thorac Dis       Date:  2016-03       Impact factor: 2.895

2.  Risk Factors of Postoperative Delirium in the Intensive Care Unit After Liver Transplantation.

Authors:  Hannah Lee; Seung-Young Oh; Je Hyuk Yu; Jeongsoo Kim; Sehee Yoon; Ho Geol Ryu
Journal:  World J Surg       Date:  2018-09       Impact factor: 3.352

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.